![]() In PNH, most symptoms that the patients experience results due to intravascular hemolysis. The reasons for these variations are not clear. It is more common in residents of Asia, the Pacific Islands, and Latin America. They have also demonstrated bone marrow failure to vary with ethnicity or geography. African-Americans with PNH have a 73% rate of thromboembolism (TE) and Latin Americans, about 50%. White race and Asian Americans have a 36% rate of TE complications. Patients affected by PNH in the US demonstrate differences in complications according to ethnic groups. Consequently, the incidence of thromboembolism due to PNH is higher in the US and Europe compared to Japan. For instance, about 30 to 40% of PNH cases are reported in the United States(US) and Europe, whereas less than 10% of PNH cases are reported from Asia. While the occurrence of PNH has no apparent ethnic or geographic distribution, there is an increased risk of thrombosis in the United States and Europe. The difference in this expression of PIGA mutation is that it affects granulocytes rather than erythrocytes, and hemolysis does not occur. There has been a variant of the mutation, a hypomorphic PIGA mutation that is responsible for a syndrome known as multiple congenital anomalies-hypotonia-seizures syndromes. These children have severe congenital manifestations, including intellectual disability, abnormal facial features, seizures, and death at an early age. The PIGA mutation that is responsible for PNH can also occur in germline cells however, this generally results in embryonic death. Therefore, once the mutation occurs, the cell line perpetuates the abnormality until clonal superiority is achieved, and the phenotype is expressed. Men only have one X chromosome, and women only express a single X chromosome due to lyonization, or inactivation of the duplicate X chromosome. The phenotype can be created due to a single somatic mutation. This is because the acquired defect occurs in somatic, or clone, hematopoietic stem cells, rather than germ cells. Īlthough the condition is due to an X-linked chromosome mutation, women are affected at a slightly higher rate than men. The age range of patients in the registry was 3 to 99 years. For instance, according to an analysis of 1610 patients registered in the International PNH Registry in 2012, the median age of all registered patients was 42 years, with the disease duration of 4.6 years. Children can be affected by PNH as well, but it is uncommon. Typically most patients fall in the age range of 30 years to 40 years. Some authors indicate that this number is probably low as the disease remains undiagnosed in individuals with limited symptomatology, or with comorbid conditions that obscure the PNH diagnosis. PNH is rare, with occurrence estimated as high as 15.9 individuals per million worldwide. However, in the last 15 years, advances in treatment such as the development of eculizumab have improved survival to more than 75 percent. Īlthough PNH is a rare condition, it has a significant impact on the quality of life of a patient. About 4 or 5 decades ago 10-year survival for this condition was only 50 percent. ![]() Over the following years, the nature of protein deficiencies affecting PNH erythrocytes was identified, and this paved the way for the identification of the responsible genetic mutation. ![]() While complement activation was suspected as the etiology for hemolysis, the theory was not formally proven until 1954. This resulted in the first diagnostic test for PNH, known as the Ham test (acidified serum test). Later in 1937, Ham was able to discover that erythrocytes of individuals with PNH hemolyzed when incubated with normal acidified urine. Strubing also noted that the patient's plasma was red following the most severe episodes, and he deduced that intravascular hemolysis was the cause. One of the earliest was that of Strubing, who documented the case of a young adult man with fatigue, abdominal pain, and intermittent hemoglobinuria. While the term paroxysmal nocturnal hemoglobinuria was introduced by Enneking in 1925, case reports dating back to the 1880s can be found. The condition is genetic, with the mutations occurring on the X linked gene. Other findings associated with PNH include thrombosis, renal insufficiency, and in the later course of the disease, even bone marrow failure. ![]() Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that presents clinically with a variety of symptoms, the most prevalent of which are hemolytic anemia, hemoglobinuria, and somatic symptoms including fatigue and shortness of breath. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |